Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-skin squamous cell carcinoma medicament, i.e., antagomir-365-2

A squamous cell carcinoma and skin technology, applied in the field of biomedicine, can solve problems such as difficulty in gene therapy, achieve good stability, inhibit invasion and metastasis, and inhibit and eliminate tumor mass.

Inactive Publication Date: 2012-10-31
SOUTHERN MEDICAL UNIVERSITY
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the clinical treatment of skin cancer is still based on comprehensive treatments such as surgery, radiotherapy, and laser. Today, the post-genome project has been studied, and the pathogenic genes of skin cancer have been successfully confirmed at the molecular level. However, it is still a big problem how to find the targeted therapeutic gene of tumor and carry out gene therapy on it

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-skin squamous cell carcinoma medicament, i.e., antagomir-365-2
  • Anti-skin squamous cell carcinoma medicament, i.e., antagomir-365-2
  • Anti-skin squamous cell carcinoma medicament, i.e., antagomir-365-2

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] This example relates to the experiment of inhibiting the proliferation, invasion and migration of skin squamous cell carcinoma cells by the gene fragment of the present invention.

[0029] The following experiments were divided into groups: (1) negative control group; (2) antagomir-365-2 intervention group; the skin squamous cell carcinoma cell line A431 was used in the two experiments, and the proliferation, invasion and migration of tumor cells were detected after the intervention .

[0030] The plate colony formation assay was used to detect the proliferation ability of skin squamous cell carcinoma:

[0031] A431 cells with logarithmic growth and good condition were collected, washed 3 times with D-Hanks solution, digested with 0.25% (w / v) trypsin, and the cell suspension was blown repeatedly to fully disperse the cells, and the cell concentration was adjusted to (1~ 2)×10 6 / mL, inoculate into 12-well culture plate, add 100 μL of cell suspension to each well, ge...

Embodiment 2

[0040] This example relates to the experiment of directly injecting antagomir-365-2 into the tumor to inhibit the growth of the tumor and eliminate the tumor mass.

[0041] Establishment of animal model of skin squamous cell carcinoma: A431 cells of skin squamous cell carcinoma cell line (2×10 8 1), injected subcutaneously in the right back of BALB / c nude mice; tumors grew in 4-5 days, and the size of the tumors was calculated. (tumor size (mm 3 )=D×d 2 ×π / 6 (D is the longest diameter of the tumor, d is the shortest diameter of the tumor).

[0042] Experimental groups: (1) negative control group; (2) antagomir-365-2 intervention group.

[0043] Experimental animal modeling: A431 cells were subcutaneously injected into the right back of C57BL nude mice, and each nude mouse was injected with 2×10 8 The cells formed tumors after about 5 days. Intervention measures of antagomir-365-2 in the experimental intervention group: when the tumor mass in nude mice grows to 150 mm 3 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an anti-skin squamous cell carcinoma medicament, i.e., antagomir-365-2. The antagomir-365-2 is a chemically-modified antisense oligonucleotide of which the nucleotide sequence is shown as SEQIDNO:1 in which two continuous basic groups at a 5' end and four continuous basic groups at a 3' end are modified with thiophosphoric acid, the 3' tail end is marked with cholesterol, and all basic groups are modified through methylation. The anti-skin squamous cell carcinoma medicament, i.e., antagomir-365-2 disclosed by the invention can be enriched on a target cell by overcomingthe obstacles of cell membranes, tissues and the like, can directly enter cells cultured in vitro and in-vivo tumorigenesis tissues, is an ideal medicament for performing in-vitro and in-vivo skin squamous cell carcinoma treatment experiments, and can be used for effectively inhibiting invasion and transfer of tumor cells in vitro and effectively inhibiting growth of tumors and eliminating tumorsin vivo. The antagomir-365-2 disclosed by the invention has a remarkable resisting effect on skin squamous cell carcinoma, and is a target gene medicament for treating skin cancers.

Description

Technical field [0001] The present invention is a biomedical field, which involves an anti-skin squamous cell carcinoma drug Antagomir-365-2. Background technique [0002] As one of the common malignant tumors in white races, skin cancer has a total incidence of incidence exceeding all other malignant tumors. In recent years, its incidence rate has risen year by year and showed youthful.According to the initial international agreement on restricting the consumption of ozone substances, by 2100, the incidence of skin cancer in the northwest of Europe and the American skin cancer may double, and 2060 will lead to a 10%growth peak. [0003] At present, the clinical treatment of skin cancer is still dominated by surgery, radiotherapy, laser and other comprehensive treatment. Today, the pathogenic genes of skin cancer have been successfully confirmed at the molecular level.But how to find tumor targeted therapy genes and genetic treatment on it is still a big problem. [0004] In rece...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K31/7115A61P35/00
Inventor 周美娟丁振华柳维林郑莉欧程山
Owner SOUTHERN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com